{"filings":[{"id":1369956,"accession_number":"0001420720-26-000010","cik":1420720,"company_name":"iBio, Inc.","ticker":"IBIO","form_type":"8-K","filed_at":"2026-07-01T11:33:29+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"iBio reports single-dose IBIO-610 achieves 98% Activin E inhibition at 4 weeks in obese NHP study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Single dose of IBIO-610 reduced active Activin E by 98% at week 4 and 97% at week 8 vs baseline in obese NHPs.","When combined with semaglutide, IBIO-610 reduced lean mass loss by 73% versus semaglutide alone.","Data supports potential for infrequent dosing and fat-selective weight loss while preserving lean mass.","Full dataset to be presented at EASD Annual Meeting in Milan, September 28 – October 2, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":95134446.6781915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":40643,"accession_number":"0001104659-26-059408","cik":1420720,"company_name":"iBio, Inc.","ticker":"IBIO","form_type":"8-K","filed_at":"2026-05-12T20:15:50+00:00","items":["2.02","9.01"],"status":"ready","headline":"iBio Q3: no revenue, cash $74.8M; Phase 1 clearance for IBIO-600; IBIO-610 reduces visceral fat 6.7%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["No revenue for Q3 FY2026; R&D expenses $3.3M (up $1.4M YoY); G&A $5.1M (includes $2.5M impairment of IBIO-101 intangible).","Cash, cash equivalents, and investments in debt securities $74.8M as of March 31, 2026; additional $17M from warrant exercises in Q4, extending cash runway into Q4 FY2028.","Received regulatory clearance from Australia's TGA and HREC to initiate Phase 1 trial of IBIO-600 (anti-myostatin antibody) in overweight/obese adults; first dosing expected Q2 calendar 2026.","Announced pipeline expansion into PH-HFpEF with a selective bispecific antibody blocking Activin A, GDF8, GDF11 to reduce cardiac fibrosis and vascular remodeling.","Preclinical NHP data for IBIO-610: after two doses, visceral fat reduced by 6.7%, total fat mass by 5.2% (small, not statistically powered study)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":100000.0,"consensus_period":"2026-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":95134446.6781915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92758,"accession_number":"0001104659-26-057945","cik":1420720,"company_name":"iBio, Inc.","ticker":"IBIO","form_type":"8-K","filed_at":"2026-05-08T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"iBio appoints Dr. Elizabeth Stoner to board, replaces Eef Schimmelpennink","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Stoner appointed as Class II director and Compensation Committee member, effective May 7, 2026.","She brings 35+ years pharma R&D experience; currently Entrepreneur Partner at MPM BioImpact.","Eef Schimmelpennink resigned immediately; departure not due to any disagreement with the Company.","Standard non-employee director compensation: $40k annual board fee, $7.5k committee fee, option grant.","CEO cites upcoming first human clinical trial for obesity and pulmonary hypertension therapies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":95134446.6781915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92756,"accession_number":"0001104659-26-044969","cik":1420720,"company_name":"iBio, Inc.","ticker":"IBIO","form_type":"8-K/A","filed_at":"2026-04-17T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"iBio corrects Series G warrant expiration to May 20, 2026; clinical trial for IBIO-600 cleared in Australia","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Series G warrants expire at 5:00 p.m. ET on May 20, 2026 (30 trading days after public announcement).","Outstanding Series G warrants to purchase ~11.07M shares; 36.14M shares of common stock outstanding as of April 17, 2026.","Received CTN acknowledgement from Australia's TGA and ethics approval for Phase 1 trial of IBIO-600; first dosing expected Q2 2026.","Pre-funded warrants for 13.79M shares issued upon exercise of Series G warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":95134446.6781915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92757,"accession_number":"0001104659-26-040703","cik":1420720,"company_name":"iBio, Inc.","ticker":"IBIO","form_type":"8-K","filed_at":"2026-04-08T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"iBio gets TGA/ethics approval for IBIO-600 Phase 1; warrants expire May 12","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received CTN acknowledgement from Australia's TGA and ethics committee approval to initiate first-in-human Phase 1 trial of IBIO-600.","First participant dosing expected in second quarter 2026.","IBIO-600 is a long-acting anti-myostatin monoclonal antibody designed to preserve lean mass in obesity, with potential for 2-4 doses per year.","Series G warrants (outstanding ~27.9M shares) will expire on May 12, 2026 – 30 trading days after this public announcement.","If all Series G warrants exercised, an additional ~27.9M common shares issued plus Series H warrants for same amount."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":95134446.6781915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103863,"accession_number":"0001420720-26-000006","cik":1420720,"company_name":"iBio, Inc.","ticker":"IBIO","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"iBio reports IBIO-610 reduces visceral fat 6.7%, total fat 5.2% in obese NHPs; expands into cardiopulmonary","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preclinical study: IBIO-610 reduced visceral fat by 6.7% and total fat mass by 5.2% after two doses every 8 weeks.","Extended half-life of 33.2 days in NHPs; projected human half-life up to 100 days suggesting twice-yearly dosing.","Company announces strategic expansion into cardiopulmonary space, targeting PH-HFpEF with myostatin x Activin A bispecific.","Data consistent with other Activin E pathway approaches; full dataset to be presented at scientific conferences in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":95134446.6781915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103862,"accession_number":"0001104659-26-021654","cik":1420720,"company_name":"iBio, Inc.","ticker":"IBIO","form_type":"8-K","filed_at":"2026-02-27T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"iBio enters $100M at-the-market equity agreement with Jefferies, terminates prior ATM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered Open Market Sale Agreement (ATM) with Jefferies LLC for up to $100M of common stock.","Jefferies will receive up to 3.0% commission on gross proceeds from sales.","Terminated prior ATM agreement with Chardan Capital Markets and Craig-Hallum that allowed up to $7.35M.","Sales under new ATM to be made via Nasdaq or in privately negotiated transactions, subject to conditions.","Shelf registration statement filed Feb 27, 2026; no assurance of effectiveness."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":95134446.6781915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103861,"accession_number":"0001420720-26-000003","cik":1420720,"company_name":"iBio, Inc.","ticker":"IBIO","form_type":"8-K","filed_at":"2026-02-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"iBio reports Q2 FY2026 operating loss; secures $26M PIPE financing led by Frazier Life Sciences","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["No revenue for Q2 ended Dec 31, 2025, vs $0.2M a year ago; R&D expense $4.3M, G&A $5.2M (includes impairment of IBIO-101 intangible).","Cash and investments of $52.7M at Dec 31, 2025; net proceeds of ~$24.4M from January PIPE extend runway into Q3 FY2028.","IBIO-600 (myostatin antibody) on track for Phase 1a clinical trial in H1 2026; IBIO-610 (activin E) aims for first human trials early 2027.","NHP data for IBIO-610 shows predicted human half-life up to 100 days, supporting twice-yearly dosing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":100000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":95134446.6781915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103860,"accession_number":"0001104659-26-002940","cik":1420720,"company_name":"iBio, Inc.","ticker":"IBIO","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"iBio raises $26M in PIPE led by Frazier Life Sciences to fund cardiometabolic programs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$26M from sale of 11.06M shares/pre-funded warrants at $2.35/share.","Expected close on Jan 13, 2026; led by Frazier Life Sciences with other existing investors.","Proceeds to advance IBIO-610, IBIO-600, and myostatin/activin A bispecific programs.","Company expects cash runway extended into calendar 2028.","Leerink Partners lead placement agent; LifeSci Capital and Oppenheimer co-agents."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":95134446.6781915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120133,"accession_number":"0001104659-25-114800","cik":1420720,"company_name":"iBio, Inc.","ticker":"IBIO","form_type":"8-K","filed_at":"2025-11-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"iBio shareholders elect directors, ratify auditor, approve say-on-pay at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Dr. Martin Brenner elected Class II director with 4,803,078 votes for; Dr. Alexandra Kropotova elected with 2,916,804 for.","Ratification of Grassi & Co. as auditor for FY2026 approved with 9,912,837 votes for.","Advisory say-on-pay proposal passed with 4,392,583 votes for (excluding broker non-votes).","Stockholders chose a 1-year frequency for future say-on-pay votes; company will hold annual votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":95134446.6781915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120132,"accession_number":"0001420720-25-000045","cik":1420720,"company_name":"iBio, Inc.","ticker":"IBIO","form_type":"8-K","filed_at":"2025-11-17T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"iBio updates corporate presentation for investor meetings, no specifics disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["iBio filed an updated corporate presentation dated November 2025 for use in investor meetings.","The filing includes no new financial data, guidance, or operational metrics; presentation content not appended.","Confidence is low because the actual slides are missing from this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":95134446.6781915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120131,"accession_number":"0001420720-25-000039","cik":1420720,"company_name":"iBio, Inc.","ticker":"IBIO","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"iBio Q1 FY2026 revenue $0.1M; cash $49.6M; IBIO-610 half-life up to 100 days","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $0.1M vs $0 prior year; R&D expenses $3.6M (up $2.3M YoY); G&A $2.5M (down $0.3M).","Cash $49.6M as of Sept 30, 2025, expected to fund operations into Q4 FY2027.","Closed $50M public offering; potential additional $50M from common warrant exercise for total up to $100M.","IBIO-610 NHP data shows predicted human half-life up to 100 days, enabling potential twice-yearly dosing.","Regained Nasdaq compliance on Nov 4, 2025."],"consensus_eps_estimate":-0.0639,"consensus_eps_actual":-0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":100000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":95134446.6781915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120130,"accession_number":"0001420720-25-000035","cik":1420720,"company_name":"iBio, Inc.","ticker":"IBIO","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"iBio regains Nasdaq minimum bid price compliance; deficiency notice closed","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received notice on Nov 4, 2025 from Nasdaq confirming compliance with Listing Rule 5550(a)(2).","Original deficiency letter dated July 29, 2025 for bid price below $1.00 from June 13 to July 28, 2025.","Matter is now closed; no further action required by the company.","Regained compliance after common stock (IBIO) traded at or above $1.00 for required period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":95134446.6781915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120129,"accession_number":"0001420720-25-000033","cik":1420720,"company_name":"iBio, Inc.","ticker":"IBIO","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"iBio Reports Preclinical Data for IBIO-610 Showing Extended Half-Life in Obese Non-Human Primates","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IBIO-610 half-life in obese NHP measured at 33.2 days.","Predicted human half-life up to 100 days, enabling twice-yearly dosing.","Data to be presented at ObesityWeek 2025, Nov 4-7 in Atlanta by Cory Schwartz, Ph.D.","IBIO-610 is a potential first-in-class Activin E antibody for fat-selective weight loss.","Previously showed GLP-1-synergistic weight loss and prevention of weight regain in mouse models."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":95134446.6781915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136708,"accession_number":"0001558370-25-011885","cik":1420720,"company_name":"iBio, Inc.","ticker":"IBIO","form_type":"8-K","filed_at":"2025-09-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"iBio FY2025 revenue $0.4M, cash $8.8M; advances obesity pipeline with IBIO-610 fat loss data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $0.4M (up $0.2M YoY); R&D expense $8.3M (+$3.1M); G&A $10.7M (-$1.0M).","Cash $8.8M at June 30; raised $6.2M warrant inducement; closed $50M public offering (potential +$50M on warrant exercise).","IBIO-610 (activin E) showed 26% fat mass reduction with no lean mass loss in mice; NHP study initiated.","IBIO-600 (anti-myostatin) NHP PK data demonstrated extended half-life and dose-dependent muscle growth.","Collaboration with AstralBio yielded amylin receptor antibody reducing acute food intake 60% in obese mice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":95134446.6781915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136707,"accession_number":"0001104659-25-081419","cik":1420720,"company_name":"iBio, Inc.","ticker":"IBIO","form_type":"8-K","filed_at":"2025-08-21T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"iBio prices $50M public offering of pre-funded warrants and Series G/H warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Combined offering price $0.699 per unit; gross proceeds ~$50M before underwriting discounts and expenses.","Pre-funded warrants exercisable immediately at $0.001; Series G warrants at $0.70 expire upon trial initiation milestone or 5 years.","Series H warrants expire 4 years after closing; total potential additional proceeds of ~$50M if all warrants exercised for cash.","Net proceeds to advance preclinical cardiometabolic programs IBIO-610 (myostatin/activin A bispecific) and IBIO-600.","Closing expected August 22, 2025; 90-day lock-up on share issuance for company and insiders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":95134446.6781915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136706,"accession_number":"0001104659-25-079816","cik":1420720,"company_name":"iBio, Inc.","ticker":"IBIO","form_type":"8-K","filed_at":"2025-08-18T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"iBio updates corporate presentation; posts preliminary cash of $8.8M as of June 30, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash of $8.8M as of June 30, 2025; audited FY2025 results expected later this quarter.","IBIO-610 (Activin E antibody) showed 8.9% body weight loss, 26% fat reduction, no lean mass loss in DIO mice.","IBIO-610 + semaglutide achieved 35.3% weight loss vs 27.8% alone; prevented weight regain after GLP-1 cessation.","IBIO-600 (anti-myostatin) half-life 40-52 days in NHPs; human estimate 57-147 days; CMC and GLP tox ongoing.","Partnered with AstralBio to develop amylin receptor agonist antibodies for obesity treatment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":95134446.6781915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136705,"accession_number":"0001558370-25-009992","cik":1420720,"company_name":"iBio, Inc.","ticker":"IBIO","form_type":"8-K","filed_at":"2025-08-01T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"iBio receives Nasdaq deficiency notice for bid price below $1.00, has 180 days to cure","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on July 29, 2025 for failing Minimum Bid Price of $1.00 for 30 consecutive business days.","Company has until January 26, 2026 to regain compliance by closing at $1.00+ for at least 10 consecutive business days.","If not cured, iBio may be eligible for additional 180 days if it meets other standards and notifies Nasdaq of intent to cure via reverse split.","No immediate effect on listing; stock continues trading on Nasdaq Capital Market under 'IBIO'.","Company intends to monitor bid price and consider options including reverse stock split."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":95134446.6781915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153924,"accession_number":"0001420720-25-000029","cik":1420720,"company_name":"iBio, Inc.","ticker":"IBIO","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"iBio updates corporate presentation highlighting obesity and cardiometabolic disease antibodies","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed updated corporate presentation dated June 2025 for investor meetings.","Presentation focuses on breakthrough antibodies for obesity and cardiometabolic diseases.","No financial or pipeline specifics disclosed in the filing or attached exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":95134446.6781915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153923,"accession_number":"0001420720-25-000027","cik":1420720,"company_name":"iBio, Inc.","ticker":"IBIO","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"iBio extends $1.5M promissory note maturity with Safi Biotherapeutics to June 19, 2026","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Note originally issued June 19, 2023 in principal amount of $1,500,000.","Maturity extended from June 19, 2025 to June 19, 2026 by mutual consent.","All accrued interest must be paid at the time of the extension.","Extension agreement dated June 17, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":95134446.6781915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153922,"accession_number":"0001420720-25-000024","cik":1420720,"company_name":"iBio, Inc.","ticker":"IBIO","form_type":"8-K","filed_at":"2025-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"iBio Q3 FY2025 net loss widens to $4.9M; pipeline progress with IBIO-600, Activin E","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss from continuing ops $4.9M ($0.49/share) vs $2.6M ($0.71/share) in Q3 FY2024.","R&D expenses doubled to $1.9M on advancing IBIO-600 and Activin E programs.","Cash $5.2M at March 31; after $6.2M warrant inducement in April, cash ~$10.5M as of May 1.","In-licensed first-in-class Activin E antibody from AstralBio; reported NHP data for IBIO-600 showing dose-dependent muscle growth.","Trading began on Nasdaq under IBIO; on track for IBIO-600 regulatory submission in 2026."],"consensus_eps_estimate":-0.1046,"consensus_eps_actual":-1.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":200000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":95134446.6781915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153921,"accession_number":"0001420720-25-000020","cik":1420720,"company_name":"iBio, Inc.","ticker":"IBIO","form_type":"8-K","filed_at":"2025-04-22T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"iBio licenses first-in-class anti-Activin E antibody from AstralBio for up to $28M in milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront $750K credit applied toward option fee; total milestone payments up to $28M, payable in cash or stock.","Antibody demonstrated fat-selective weight loss and synergy with GLP-1 in obese rodent model.","iBio also amended AstralBio collaboration to add a fifth cardiometabolic target using its AI platform.","AstralBio eligible for low to mid-single-digit sublicense fees on any sublicense proceeds.","iBio solely responsible for all development, manufacturing, and commercialization worldwide."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":95134446.6781915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153920,"accession_number":"0001420720-25-000018","cik":1420720,"company_name":"iBio, Inc.","ticker":"IBIO","form_type":"8-K","filed_at":"2025-04-08T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"iBio reveals preclinical data for IBIO-600 and Activin E antibody combo with semaglutide","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IBIO-600 NHP study: half-life 40-52 days, potential human half-life up to 130 days; dose-dependent lean mass increase and fat reduction.","Activin E monotherapy in obese mice: ~4% weight loss, 18% fat reduction vs placebo after two weeks.","Activin E + semaglutide combination: 34% total weight loss (9% above semaglutide alone), 72% body fat reduction by DEXA.","Both candidates target obesity and cardiometabolic diseases; IBIO-600 is anti-myostatin, Activin E induces fat-selective weight loss."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":95134446.6781915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153919,"accession_number":"0001420720-25-000016","cik":1420720,"company_name":"iBio, Inc.","ticker":"IBIO","form_type":"8-K","filed_at":"2025-04-07T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"iBio reports IBIO-600 NHP half-life up to 52 days; Activin E antibody shows 34% weight loss with semaglutide","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IBIO-600 NHP half-life 40-52 days; estimated human half-life up to 130 days, enabling once every 3-6 month dosing.","IBIO-600 promoted dose-dependent lean mass increase (3.1% low-dose, 5.1% high-dose) and fat reduction in NHPs after 8 weeks.","Activin E antibody monotherapy in obese mice: 4% weight loss, 18% total body fat reduction vs placebo after 2 weeks.","Activin E antibody combined with semaglutide: 34% total weight loss, 72% fat reduction – synergistic beyond GLP-1 alone.","iBio on track for IBIO-600 regulatory submission in Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":95134446.6781915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172573,"accession_number":"0001420720-25-000014","cik":1420720,"company_name":"iBio, Inc.","ticker":"IBIO","form_type":"8-K","filed_at":"2025-02-19T23:59:59+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"iBio voluntarily delists from NYSE American, lists on Nasdaq Capital Market effective March 4, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized voluntary withdrawal from NYSE American and listing on Nasdaq Capital Market on Feb 19, 2025.","Last NYSE American trade expected at market close March 3, 2025; Nasdaq trading starts market open March 4, 2025.","Ticker symbol 'IBIO' remains unchanged on both exchanges.","CEO Martin Brenner says move expected to improve stock visibility, trading liquidity, and institutional investor exposure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":95134446.6781915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172572,"accession_number":"0001420720-25-000010","cik":1420720,"company_name":"iBio, Inc.","ticker":"IBIO","form_type":"8-K","filed_at":"2025-02-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"iBio Q2 FY2025 net loss $4.4M; cash $7.2M; advances pipeline","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $0.2M; net loss $4.4M ($0.48/shr) vs $4.5M ($2.42/shr) prior year.","Cash & equivalents $7.2M as of Dec 31, 2024, including $0.2M restricted.","Discovered novel Activin E antibody; in-licensed anti-myostatin IBIO-600 in Jan 2025.","Initiated bispecific myostatin/activin A program; plans clinical investigation in 2026.","Board added David Arkowitz and António Parada; insider private placement closed Jan 2025."],"consensus_eps_estimate":-0.3723,"consensus_eps_actual":-0.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":200000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":95134446.6781915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172571,"accession_number":"0001420720-25-000005","cik":1420720,"company_name":"iBio, Inc.","ticker":"IBIO","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"iBio raises $655K via insider stock placement; officers and directors buy 240,807 shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Private placement of 240,807 shares at $2.72/share, gross proceeds ~$655K.","Investors include certain officers and directors, signaling insider confidence.","Net proceeds to be used for working capital purposes.","Offering exempt from registration under Regulation D, no public offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":95134446.6781915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172570,"accession_number":"0001420720-25-000003","cik":1420720,"company_name":"iBio, Inc.","ticker":"IBIO","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"iBio develops Activin E antibody for obesity; preclinical data shows sub-nanomolar binding","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Antibody targeting Activin E for cardiometabolic disorders and obesity, developed with AstralBio Inc.","Preclinical data: sub-nanomolar binding kinetics and complete blockade of Activin E signaling in human adipocytes.","Utilized iBio's AI platform to engineer antibodies targeting five epitopes on Activin E protein.","Corporate presentation updated to reflect the new antibody program; used in investor meetings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":95134446.6781915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172569,"accession_number":"0001420720-25-000001","cik":1420720,"company_name":"iBio, Inc.","ticker":"IBIO","form_type":"8-K","filed_at":"2025-01-02T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"iBio licenses anti-myostatin antibody IBIO-600 from AstralBio; launches bispecific program for obesity","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront payment of $750,000 paid in common stock; milestones up to $28M.","IBIO-600 is a long-acting anti-myostatin antibody designed for subcutaneous use.","iBio initiated a bispecific antibody program targeting myostatin/activin A for obesity and cardiometabolic disorders.","Preclinical studies show potent myostatin inhibition; NHP data expected early 2025.","Plans to enter clinical trials in obesity and cardiometabolic disorders in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":95134446.6781915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189566,"accession_number":"0001104659-24-122387","cik":1420720,"company_name":"iBio, Inc.","ticker":"IBIO","form_type":"8-K","filed_at":"2024-11-25T23:59:59+00:00","items":["2.02","5.07","9.01"],"status":"ready","headline":"iBio appoints David Arkowitz and António Parada as independent directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Arkowitz (Alkeus Pharma CFO) and António Parada (FairJourney Biologics CEO) join board effective Nov 25, 2024.","Arkowitz brings financial expertise; Parada adds antibody discovery depth; CEO cites alignment with next-gen strategy.","Departing director General Tom Hill thanked for 16 years of service; board now three Class I directors.","Annual meeting on Nov 21 passed all proposals: elected three directors, ratified Grassi & Co., and approved say-on-pay."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":95134446.6781915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189565,"accession_number":"0001420720-24-000053","cik":1420720,"company_name":"iBio, Inc.","ticker":"IBIO","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"iBio Q1 fiscal 2025: net loss $4.0M ($0.46/sh), no revenue; advancing myostatin NHP study","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["No revenue for quarter ended Sep 30, 2024; net loss from continuing ops $4.0M ($0.46/sh) vs $5.1M ($4.24/sh) YoY.","R&D and G&A expenses decreased ~20% YoY to $4.1M as part of cash preservation strategy.","Cash, equivalents, and restricted cash $11.3M at Sep 30, 2024 (incl $0.2M restricted).","Collaboration with AstralBio: lead molecule for muscle wasting/obesity dosed in NHP study; early readouts expected early 2025.","Appointed Kristi Sarno as SVP of Business Development effective Aug 1, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":95134446.6781915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189564,"accession_number":"0001420720-24-000049","cik":1420720,"company_name":"iBio, Inc.","ticker":"IBIO","form_type":"8-K","filed_at":"2024-10-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"iBio updates corporate presentation; no specific material changes disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["iBio furnished an updated corporate presentation dated October 2024, focused on precision antibody therapeutics powered by machine learning.","No new financial guidance, pipeline milestones, or operational metrics were provided in the 8-K filing.","The presentation is furnished under Regulation FD and not incorporated by reference into SEC filings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":95134446.6781915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206070,"accession_number":"0001420720-24-000036","cik":1420720,"company_name":"iBio, Inc.","ticker":"IBIO","form_type":"8-K","filed_at":"2024-09-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"iBio FY2024 net loss $24.9M; revenue $0.2M; auditor raises going concern","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss narrowed to $24.9M from $65M YoY; R&D expense fell $5.1M, G&A fell $7.3M.","Cash, equivalents, restricted cash $14.4M at June 30, 2024; going concern warning in audit opinion.","Sold Texas manufacturing facility to Texas A&M for $8.5M, eliminating $13.2M secured debt.","Sold PD-1 asset to Otsuka for $1M upfront plus up to $52.5M milestones; entered AstralBio collaboration.","Raised ~$24M in equity (public offer $4.5M, PIPE $15M, warrant exercise $4.5M) after 1:20 reverse split."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":95134446.6781915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206069,"accession_number":"0001420720-24-000032","cik":1420720,"company_name":"iBio, Inc.","ticker":"IBIO","form_type":"8-K","filed_at":"2024-07-26T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"iBio amends CEO Martin Brenner's agreement; base salary $522K, bonus target raised to 50% for FY2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Base salary set at $522,365; FY2025 bonus target increased to 50% of base salary, FY2024 remains 40%.","Severance without cause or for good reason includes 12 months salary, pro-rata bonus, and COBRA coverage.","Upon Sale Event termination: 18 months salary, target bonus, and accelerated vesting of time-vested equity.","Employment is at-will; includes standard termination benefits and non-solicitation/invention assignment clauses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":95134446.6781915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206068,"accession_number":"0001420720-24-000029","cik":1420720,"company_name":"iBio, Inc.","ticker":"IBIO","form_type":"8-K","filed_at":"2024-07-09T23:59:59+00:00","items":["5.02","5.05","9.01"],"status":"ready","headline":"iBio adopts standard equity award forms and updates Code of Business Conduct","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved forms of stock option and RSU agreements for directors, officers, employees, and consultants under the 2023 Plan.","Award agreements include provisions for exercise price payment methods, vesting schedules, and termination treatment.","Updated Code of Business Conduct and Ethics to modernize language and enhance risk mitigation.","No executive departures, new appointments, or financial guidance changes were disclosed.","Actions are routine governance updates with no immediate material financial impact."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":95134446.6781915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206067,"accession_number":"0001104659-24-077791","cik":1420720,"company_name":"iBio, Inc.","ticker":"IBIO","form_type":"8-K","filed_at":"2024-07-03T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"iBio enters ATM equity facility for up to $7.35M in common stock sales","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entry into ATM Agreement with Chardan Capital Markets and Craig-Hallum Capital Group for at-the-market offerings.","Aggregate market value of shares eligible for sale under the ATM prospectus supplement is $7,350,000.","Sales agents receive fixed commission rate of up to 3.0% of gross proceeds.","Shelf registration statement on Form S-3 filed on July 3, 2024, must be effective before sales can occur.","Company has no obligation to sell shares and may suspend offerings at any time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":95134446.6781915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223100,"accession_number":"0001420720-24-000027","cik":1420720,"company_name":"iBio, Inc.","ticker":"IBIO","form_type":"8-K","filed_at":"2024-06-05T23:59:59+00:00","items":["1.02","2.01","3.02","7.01","9.01"],"status":"ready","headline":"iBio sells Texas facility, eliminates $13.2M debt, completes AI biotech pivot","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sale of Bryan, TX manufacturing facility to Texas A&M Board of Regents for $8.5M cash.","Cash of $8.5M plus $915K restricted cash and $4.5M pre-funded warrant eliminates $13.2M secured debt.","Pre-funded warrant issued to Woodforest Bank for 1,560,570 shares at $0.0001 per share.","CEO Martin Brenner says sale completes transition from CDMO to AI-driven precision biologics company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":95134446.6781915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223099,"accession_number":"0001558370-24-008860","cik":1420720,"company_name":"iBio, Inc.","ticker":"IBIO","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"iBio updates corporate presentation; no financial or operational specifics disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filed updated investor presentation dated June 2024 under Item 7.01.","Presentation title: 'Tomorrow's Precision Antibody Therapeutics Powered by Machine Learning'.","No new financial data, guidance, or material business changes were included in the filing.","The presentation is furnished, not filed, and not incorporated by reference.","No forward-looking statements or new milestones were provided beyond prior disclosures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":95134446.6781915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223098,"accession_number":"0001420720-24-000023","cik":1420720,"company_name":"iBio, Inc.","ticker":"IBIO","form_type":"8-K","filed_at":"2024-05-20T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"iBio sells Texas property to Texas A&M for $8.5M; issues 1.56M share warrant to settle Woodforest debt","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["iBio CDMO sells Texas A&M property for $8.5M; closing by May 31, 2024.","Credit agreement balance $13.1M; maturity accelerated to May 31, 2024.","Settlement: sale proceeds to Woodforest; pre-funded warrant for 1,560,570 shares issued at $0.0001/share to cover $4.5M deficiency.","Warrant issued unregistered under Regulation D; NYSE American approval required.","Texas A&M board approval already obtained; closing subject to title policy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":95134446.6781915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223097,"accession_number":"0001420720-24-000018","cik":1420720,"company_name":"iBio, Inc.","ticker":"IBIO","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"iBio Q3 net loss $2.6M; cash raised to $17.9M via PIPE; enters AstralBio collaboration","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss from continuing ops: $2.6M ($0.71/share) vs $6.3M ($9.53/share) YoY; no revenue.","R&D expenses down 66%, G&A down 23% YoY under cash preservation strategy.","Cash and equivalents $17.9M after $15M PIPE closed in April, up from $6.4M at March 31.","Partnered with AstralBio to develop 4 antibody targets for obesity/cardiometabolic diseases.","Sold early-stage PD-1 asset to Otsuka for $1M upfront and up to $52.5M in contingent payments."],"consensus_eps_estimate":null,"consensus_eps_actual":-7.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":50000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":95134446.6781915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223096,"accession_number":"0001420720-24-000015","cik":1420720,"company_name":"iBio, Inc.","ticker":"IBIO","form_type":"8-K","filed_at":"2024-04-01T23:59:59+00:00","items":["1.01","3.02","7.01","8.01","9.01"],"status":"ready","headline":"iBio raises ~$15.1M in PIPE at $2.85/unit (148% premium), extends cash runway through FY2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$15.1M from common shares, pre-funded warrants, and Series E warrants at $2.85 per unit.","Net proceeds of ~$14.1M; intended for R&D and working capital, extending cash runway through fiscal 2025.","Series E warrants exercisable after 6 months at $2.64/share for 5 years; $2.85 price represents 148% premium to last close.","Amended credit agreement with Woodforest National Bank, extending term loan maturity to May 15, 2024.","Q3 FY2024 saw exercise of 1,131,500 Class C and 1,006,500 Class D warrants; shares outstanding now 8,515,226."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":95134446.6781915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242598,"accession_number":"0001420720-24-000012","cik":1420720,"company_name":"iBio, Inc.","ticker":"IBIO","form_type":"8-K","filed_at":"2024-02-26T23:59:59+00:00","items":["1.01","2.01","7.01","9.01"],"status":"ready","headline":"iBio sells PD-1 agonist program to Otsuka for $1M upfront; up to $52.5M milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Otsuka acquired iBio's PD-1 agonist assets; $1M cash at closing, up to $52.5M in development and commercial milestones.","iBio originally acquired the PD-1 assets from RubrYc Therapeutics in September 2022; no related milestone obligations.","Deal closes Feb 25, 2024; iBio will redirect resources to its proprietary immuno-oncology pipeline and AI platform.","PD-1 agonists target autoimmune diseases; CEO Martin Brenner calls transaction a win-win and non-dilutive capital source."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":95134446.6781915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242597,"accession_number":"0001420720-24-000008","cik":1420720,"company_name":"iBio, Inc.","ticker":"IBIO","form_type":"8-K","filed_at":"2024-02-21T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"iBio replaces auditor CohnReznick with Grassi; prior audit included going concern note","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit Committee approved Grassi & Co. as new auditor for FY ending June 30, 2024; engagement effective Feb 20, 2024.","CohnReznick resigned effective Feb 15, 2024; its FY2023 report included a going concern explanatory paragraph.","No disagreements or reportable events, apart from a remediated material weakness in stock-based compensation accounting.","Resignation not initiated by Audit Committee; competitive process led to selection of Grassi."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":95134446.6781915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242596,"accession_number":"0001420720-24-000005","cik":1420720,"company_name":"iBio, Inc.","ticker":"IBIO","form_type":"8-K","filed_at":"2024-01-19T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"iBio secures $1.07M term loan from Loeb Term Solutions at Prime+8.5%, collateralized by assets except IP","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Loan principal $1,071,572; net proceeds ~$1,027,455 after $42,863 origination fee.","Interest at Prime Rate +8.5%; monthly payments over 4-year amortization, balloon due at 2 years.","Secured by substantially all assets except filed patent-related IP.","Personal indemnity guarantees from executives Dr. Martin Brenner and Felipe Duran.","Prepayment fees: 4% (first 12 months), 3% (second 12 months)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":95134446.6781915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242595,"accession_number":"0001420720-24-000002","cik":1420720,"company_name":"iBio, Inc.","ticker":"IBIO","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"iBio files updated corporate presentation; no financial details in filing","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company furnished a new investor presentation dated January 2024 as Exhibit 99.1.","Presentation title emphasizes precision antibody therapeutics and machine learning.","No specific financial metrics, guidance, or operational updates disclosed in the filing text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":95134446.6781915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259978,"accession_number":"0001420720-23-000072","cik":1420720,"company_name":"iBio, Inc.","ticker":"IBIO","form_type":"8-K","filed_at":"2023-12-26T23:59:59+00:00","items":["1.01","2.03","7.01","9.01"],"status":"ready","headline":"iBio amends credit agreement: maturity extended to March 29, 2024, rate cut to 4.5%","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Maturity extended from Dec 31, 2023 to earlier of March 29, 2024 or acceleration of term loan.","Interest rate reduced from 5.25% to 4.5%; payment-in-kind increased from 3% to 4.5%.","Borrower must maintain minimum $900K reserve; best efforts to sell cGMP manufacturing facility before maturity.","Woodforest fee increased by $10,000 to $155,000, payable at sale closing or maturity date.","Amendment provides additional flexibility to complete divestiture of CDMO business and advance AI immunotherapy platform."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":95134446.6781915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259977,"accession_number":"0001420720-23-000068","cik":1420720,"company_name":"iBio, Inc.","ticker":"IBIO","form_type":"8-K","filed_at":"2023-12-08T23:59:59+00:00","items":["3.02","8.01","9.01"],"status":"ready","headline":"iBio closes public offering of common stock and warrants, raising ~$4.5M gross proceeds","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering included 600K shares common stock, 1.65M pre-funded warrants, and 4.5M Series C/D warrants exercisable at $2.00.","Gross proceeds of ~$4.5M; net proceeds for working capital, R&D, trial preparation, and severance payments.","Placement agents A.G.P./Alliance Global Partners (lead) and Brookline Capital Markets receive 5.5% cash fee plus expense reimbursement.","Tail warrants issued to H.C. Wainwright for 131,820 shares at $2.50 exercise price if certain investors participate."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":95134446.6781915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259976,"accession_number":"0001104659-23-123841","cik":1420720,"company_name":"iBio, Inc.","ticker":"IBIO","form_type":"8-K","filed_at":"2023-12-06T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"iBio prices $4.5M public offering of common stock and warrants at $2.00/unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds $4.5M; net proceeds ~$3.6M after fees and expenses.","Offering comprises 2.25M shares (or pre-funded warrants) plus Series C (2-year) and Series D (5-year) warrants.","Series C and D warrants each exercisable for one share at $2.00, immediately exercisable.","Closing expected Dec 7, 2023; proceeds for working capital, R&D, and severance payments.","A.G.P./Alliance Global Partners lead placement agent; Brookline Capital Markets co-placement agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":95134446.6781915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259975,"accession_number":"0001420720-23-000065","cik":1420720,"company_name":"iBio, Inc.","ticker":"IBIO","form_type":"8-K","filed_at":"2023-11-28T23:59:59+00:00","items":["3.03","5.03","5.02","5.07","7.01","9.01"],"status":"ready","headline":"iBio effects 1-for-20 reverse stock split, reduces outstanding shares from 28.1M to 1.4M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1:20 effective 12:01 a.m. ET Nov 29, 2023; shares continue trading as IBIO.","Outstanding shares reduced from 28,100,733 to 1,405,036; fractional shareholders to receive cash.","Stockholders approved reverse split with 5.8M for vs 5.2M against at Nov 27 annual meeting.","Also adopted 2023 Omnibus Incentive Plan and elected directors Clark and Sender.","New CUSIP number is 451033708; transfer agent Continental Stock Trust handling exchanges."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":95134446.6781915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259974,"accession_number":"0001420720-23-000054","cik":1420720,"company_name":"iBio, Inc.","ticker":"IBIO","form_type":"8-K","filed_at":"2023-10-10T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"iBio amends credit agreement to access $2M from reserve; reduces cash covenant to $0","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Seventh Amendment allows iBio CDMO to withdraw up to $1M immediately with $2M min balance; then $750k after Oct 16 with $1.25M min; then $250k after Nov 13 with $1M min.","Fifth Amendment to Guaranty reduces iBio's unrestricted cash liquidity covenant from $1M to $0.","iBio to pay Woodforest $20k fee upon earlier of Purchase Agreement closing or Maturity Date.","Amendments provide iBio increased cash flexibility while maintaining reserve until full repayment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":95134446.6781915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-10-10T23:59:59+00:00|259974"}